Prasugrel STEMI subgroup analysis

The Lancet

Volumn 373, Issue 9678, 2009, Pages 1846-

  Shil, Asit Baran ^a   Strohm, Maureen P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL; THIENOPYRIDINE DERIVATIVE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

BLOOD CLOTTING PARAMETERS; CLINICAL PRACTICE; HEART INFARCTION; HUMAN; LETTER; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STOMACH ABSORPTION; THROMBOCYTE;

EID: 65849268315     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61021-7     Document Type: Letter

References (5)

1. Montalescot G., Wiviott S.D., Braunwald E., et al., for the TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 (2009) 723-731
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
3. Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
4. Le Manach Y., Godet G., Coriat P., et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 104 (2007) 1326-1333
5. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336 (1990) 827-830